Asset Details
Do you wish to reserve the book?
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial
Do you wish to request the book?
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial
2025
Overview
Hepatic fibrosis, resulting from chronic liver injury, can lead to cirrhosis and liver failure. Curcumin shows anti-fibrotic potential but has low bioavailability. This 16-week double-blind, randomized, placebo-controlled trial evaluated the effects of 80 mg/day nano-curcumin on liver fibrosis, steatosis, liver function test, and anthropometric parameters in 55 adults (30–70 years) with stage ≥ F2 NAFLD-induced fibrosis. Primary outcomes were liver fibrosis and steatosis assessed by FibroScan and FIB-4. Secondary outcomes included changes in liver function tests and anthropometric parameters including body composition. Both groups improved in fibrosis and steatosis, with no significant differences were found between them. The FIB-4 index decreased significantly in the nano-curcumin group (
p
= 0.022), but between-group differences were not significant (
p
= 0.135). ALT and AST significantly decreased in the nano-curcumin group (
p
< 0.001 and
p
= 0.004), with significant group differences (
p
< 0.05). GGT reduction was significant between groups after adjustment (
p
= 0.043), and LDH levels also decreased significantly in the nano-curcumin group (
p
< 0.001), with a significant between-group difference (
p
= 0.016). No statistically significant between-group differences were observed in anthropometric parameters. Nano-curcumin improved liver enzymes but showed no significant effect on fibrosis or steatosis compared to placebo. Further research is needed to confirm long-term benefits.
Trial registration
Iranian Registry of Clinical Trials IRCT20210427051098N2 (Available from:
https://irct.behdasht.gov.ir
).
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/699
/ 692/700
/ Adult
/ Aged
/ Biopsy
/ Curcumin
/ Curcumin - administration & dosage
/ Female
/ Fibrosis
/ Humanities and Social Sciences
/ Humans
/ Liver
/ Liver Cirrhosis - diet therapy
/ Male
/ Non-alcoholic Fatty Liver Disease - complications
/ Non-alcoholic Fatty Liver Disease - diet therapy
/ Patients
/ Placebos
/ Science
